한국의 경제뉴스통신사 - NSP통신.

(Seoul=NSP NEWS) = On 10 May, Olix Pharmaceuticals terminated the licensing agreement in Asia with Hugel for hypertrophic scar treatment, OLX101A.

The termination was due to a change in the internal policy of Hugel. The two companies agreed on returning the technology and license alike.

Therefore, Olix Pharmaceuticals becomes the only company with the exclusive right to develop OLX101A treatment globally. Based on the rights, the pharmaceutical company planned to speed up the ongoing conversation on licensee agreements with numerous global pharmaceutical and cosmetic companies.

By Hyun-jin Kim(kimhj30310@nspna.com) and Da-eun Kim(ekdms8381@nspna.com)

ⓒNSP News Agency·NSP TV. All rights reserved.